Background: There is currently no consensus treatment for children non-responsive to peginterferon (Peg-IFN) and ribavirin.
Case Presentation: Here, we present a Japanese child with chronic hepatitis C with fibrosis, who did not respond to Peg-IFN α-2b but responded to Peg-IFN α-2a with ribavirin, accompanied with fluvastatin. To date, there has been no reported case of re-treatment in children. The early viral response occurred soon after starting treatment using Peg-IFN α-2a/ribavirin plus fluvastatin.
Conclusion: Our result indicates that when treatment by Peg-IFN α-2b/ribavirin combination therapy is not efficient, combination therapy using Peg-IFN α-2a/ribavirin plus fluvastatin should be considered in children with advanced liver change.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jiac.2014.02.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of 48-week pegylated interferon--2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study.
Front Med (Lausanne)
December 2024
Department of Hepatology, The Third People's Hospital of Taiyuan, Taiyuan, Shanxi Province, China.
Background: Pegylated interferon- (PEG-IFN-α) therapy could decrease hepatitis B surface antigen (HBsAg) and improve long-term prognosis of hepatitis B virus (HBV) infection. However, studies on safety and efficacy of PEG-IFN- for patients with HBV-related cirrhosis are limited.
Methods: This was a single-center study.
Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens.
World J Gastroenterol
November 2024
Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China.
Background: The long-term stability of hepatitis B surface antigen (HBsAg) seroclearance following peginterferon alpha (peg-IFN-α)-based therapy has not been extensively studied, leaving the full potential and limitations of this strategy unclear.
Aim: To assess HBsAg recurrence after seroclearance achieved by peg-IFN-α regimens.
Methods: This prospective, multicenter, observational study was conducted from November 2015 to June 2021 at three Chinese hospitals: The Second Affiliated Hospital of Xi'an Jiaotong University, Ankang Central Hospital, and The Affiliated Hospital of Yan'an University.
Chronic Hepatitis D Virus Infection and Its Treatment: A Narrative Review.
Microorganisms
October 2024
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Article Synopsis
- * Current treatments, primarily pegylated interferon (PEG-IFN), can suppress HDV but have low cure rates and significant side effects, making their use challenging.
- * New antiviral therapies are being developed that target different stages of HDV replication, showing potential for better long-term treatment results when used alongside PEG-IFN.
The efficacy and safety of addition of pegylated interferon to long-term nucleos(t)ide analogue therapy on functional cure of chronic hepatitis B patient: a systematic review and meta-analysis.
Front Pharmacol
October 2024
Tongzhou District of Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Objective: This meta-analysis aims to assess the efficacy and safety of adding pegylated interferon (Peg-IFN) to long-term nucleos(t)ide analogs (NAs) treatment for achieving functional cure in patients with chronic hepatitis B (CHB).
Methods: This meta-analysis was registered in PROSPERO (CRD42024519116). We searched PubMed, Embase, Cochrane Library and Web of Science for randomized controlled trials that compared adding Peg-IFN to long-term NAs with NAs alone for the treatment of CHB.
HBV Antigen-Guided Switching Strategy From Nucleos(t)ide Analogue to Interferon: Avoid Virologic Breakthrough and Improve Functional Cure.
J Med Virol
November 2024
Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Article Synopsis
- A study involving 80 patients with chronic hepatitis B (CHB) found that 15% experienced virologic breakthrough (VBT) after switching from nucleos(t)ide analogue (NA) therapy to pegylated interferon alpha (Peg-IFN-α) treatment.
- Patients who had higher levels of HBcrAg (≥5 logU/mL) and HBsAg (≥100 IU/mL) showed a significantly increased risk of VBT and were less likely to achieve HBsAg clearance post-therapy.
- The research indicates that monitoring HBcrAg and HBsAg levels can provide insights into immune responses and help prevent VBT, potentially improving the chances of achieving a functional cure for CH
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!